ARCA biopharma, Inc. Contracts & Agreements

Form of Registration Rights Agreement, dated as of August 29, 2024 (Filed With SEC on November 13, 2024)

Amended and Restated Employment Letter Agreement by and between the Company and Dr. Lawrence Klein, dated as of October 3, 2024 (Filed With SEC on October 4, 2024)

Amended and Restated Employment Letter Agreement by and between the Company and Arjun Agarwal, dated as of October 3, 2024 (Filed With SEC on October 4, 2024)

Form of Pre-Funded Warrant (Filed With SEC on September 13, 2024)

Securities Purchase Agreement, dated September 11, 2024, by and between Oruka Therapeutics, Inc. and each purchaser identified on Annex A thereto (Filed With SEC on September 13, 2024)

Form of Registration Rights Agreement (Filed With SEC on September 13, 2024)

Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (Filed With SEC on September 5, 2024)

Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (Filed With SEC on September 5, 2024)

Second Amendment to Amended and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, effective as of May 7, 2024 (Filed With SEC on September 5, 2024)

Form of Employee Warrant Agreement (Filed With SEC on September 5, 2024)

Consulting Agreement, effective as of August 30, 2024, by and between Oruka Therapeutics, Inc. and Jeff Dekker (Filed With SEC on September 5, 2024)

Asset Purchase Agreement, dated August 14, 2024, by and between ARCA biopharma, Inc. and Genvara Biopharma, Inc (Filed With SEC on August 15, 2024)

Form of Amendment (Filed With SEC on July 9, 2024)

Form of A&R Subscription Agreement (Filed With SEC on July 9, 2024)

Investor Rights Agreement, dated March 6, 2024, by and among Oruka Therapeutics, Inc. and certain parties thereto (Filed With SEC on May 14, 2024)

Amended and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, as amended by the First Amendment dated May 7, 2024 (Filed With SEC on May 14, 2024)

Form of Restricted Stock Notice and Restricted Stock Purchase Agreement of Oruka Therapeutics, Inc (Filed With SEC on May 14, 2024)

Form of Stock Option Agreement under Oruka Therapeutics, Inc. 2024 Equity Incentive Plan (Filed With SEC on May 14, 2024)

Amended and Restated Director Offer Letter, dated March 22, 2024, between Oruka Therapeutics, Inc. and Samarth Kulkarni (Filed With SEC on May 14, 2024)

Director Offer Letter, dated April 24, 2024, between Oruka Therapeutics, Inc. and Kristine Ball (Filed With SEC on May 14, 2024)

Form of Indemnification Agreement between Oruka Therapeutics, Inc. and its directors and officers (Filed With SEC on May 14, 2024)

Amended and Restated Employment Offer Letter, dated February 14, 2024, by and between Oruka Therapeutics, Inc. and Lawrence Klein (Filed With SEC on May 14, 2024)

Employment Offer Letter, dated March 11, 2024, by and between Oruka Therapeutics, Inc. and Arjun Agarwal (Filed With SEC on May 14, 2024)

Employment Offer Letter, dated March 15, 2024, by and between Oruka Therapeutics, Inc. and Joana Goncalves (Filed With SEC on May 14, 2024)

Employment Offer Letter, dated April 12, 2024, by and between Oruka Therapeutics, Inc. and Paul Quinlan (Filed With SEC on May 14, 2024)

Second Amendment to Retention Bonus Letter, dated April 22, 2024, by and between ARCA biopharma, Inc. and Thomas A. Keuer (Filed With SEC on April 23, 2024)

Second Amendment to Retention Bonus Letter, dated April 22, 2024, by and between ARCA biopharma, Inc. and C. Jeffrey Dekker (Filed With SEC on April 23, 2024)

Separation Agreement and Release, by and between ARCA and Michael Bristow, dated as of April 3, 2024 (Filed With SEC on April 4, 2024)

Consulting Agreement, by and between ARCA and Michael Bristow, dated as of April 3, 2024 (Filed With SEC on April 4, 2024)

Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024, by and among ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub II LLC and Oruka... (Filed With SEC on April 3, 2024)

Form of Oruka Support Agreement (Filed With SEC on April 3, 2024)

Form of Oruka Subscription Agreement (Filed With SEC on April 3, 2024)

Form of ARCA Support Agreement (Filed With SEC on April 3, 2024)

Form of Lock-Up Agreement (Filed With SEC on April 3, 2024)

First Amendment to Office Lease Agreement, dated March 19, 2024, by and between ARCA biopharma, Inc. and Lotus Church Ranch, LLC (Filed With SEC on March 22, 2024)

Amendment to Retention Bonus Letter, dated December 4, 2023, by and among ARCA biopharma, Inc. and Thomas A. Keuer (Filed With SEC on December 4, 2023)

Amendment to Retention Bonus Letter, dated December 4, 2023, by and among ARCA biopharma, Inc. and C. Jeffrey Dekker (Filed With SEC on December 4, 2023)

Memorandum Regarding Cash Retention Bonus between ARCA biopharma, Inc. and Thomas A. Keuer dated December 8, 2022 (Filed With SEC on December 9, 2022)

Memorandum Regarding Cash Retention Bonus between ARCA biopharma, Inc. and C. Jeffrey Dekker dated December 8, 2022 (Filed With SEC on December 9, 2022)

Cooperation Agreement, dated as of June 15, 2022, by and among ARCA biopharma, Inc., Cable Car Capital LLC, the Funicular Fund LP, Funicular Funds, LP and Jacob Ma-Weaver (Filed With SEC on June 21, 2022)

Assignment Agreement for Patent Rights, dated July 1, 2021, by and between ARCA biopharma, Inc. and University Medical Center of the Johannes Gutenberg University Mainz (Filed With SEC on August 4, 2021)

Employment Agreement, dated April 21, 2021, by and between ARCA biopharma, Inc. and C. Jeff Dekker (Filed With SEC on May 11, 2021)

Amendment No. 1 to Capital on DemandTM Sales Agreement, dated April 6, 2021, by and between ARCA biopharma, Inc. and JonesTrading Institutional Services LLC (Filed With SEC on April 6, 2021)

Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Standard) (Filed With SEC on December 23, 2020)

Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Officer) (Filed With SEC on December 23, 2020)

Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Director) (Filed With SEC on December 23, 2020)

Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2020 Equity Incentive Plan (Standard) (Filed With SEC on December 23, 2020)

Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2020 Equity Incentive Plan (Officer) (Filed With SEC on December 23, 2020)

ARCA biopharma, Inc. 2020 Equity Incentive Plan (Filed With SEC on December 10, 2020)

Office Lease Agreement, effective August 7, 2020, between ARCA biopharma, Inc. and Potens Partners LLC (Filed With SEC on August 31, 2020)

Capital on DemandTM Sales Agreement, dated July 22, 2020, by and between ARCA biopharma, Inc. and JonesTrading Institutional Services LLC (Filed With SEC on July 22, 2020)

Amendment No. 8 to Capital on DemandTM Sales Agreement, dated July 14, 2020, by and between ARCA biopharma, Inc. and JonesTrading Institutional Services LLC (Filed With SEC on July 14, 2020)

Amendment No. 7 to Capital on DemandTM Sales Agreement, dated July 2, 2020, by and between ARCA biopharma, Inc. and JonesTrading Institutional Services LLC (Filed With SEC on July 2, 2020)

Form of Pre-Funded Warrant (Filed With SEC on June 3, 2020)

Form of Stock Purchase Agreement between the Company and the Purchasers, dated as of June 2, 2020 (Filed With SEC on June 3, 2020)

Third Amendment to Office Lease Agreement, effective February 24, 2020, between ARCA biopharma, Inc. and CIO Circle Point, Limited Partnership (Filed With SEC on March 4, 2020)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 18, 2020)

Second Amendment to Office Lease Agreement by and between ARCA biopharma, Inc. and CIO Circle Point Limited Partnership, dated October 10, 2019 (Filed With SEC on November 6, 2019)

Amendment No. 6 to Capital on DemandTM Sales Agreement, dated June 28, 2019, by and between ARCA biopharma, Inc. and JonesTrading Institutional Services LLC (Filed With SEC on June 28, 2019)

Amendment No. 5 to Capital on DemandTM Sales Agreement, dated May 20, 2019, by and between ARCA biopharma, Inc. and JonesTrading Institutional Services LLC (Filed With SEC on May 20, 2019)

Amendment No. 4 to Capital on DemandTM Sales Agreement, dated May 9, 2019, by and between ARCA biopharma, Inc. and JonesTrading Institutional Services LLC (Filed With SEC on May 9, 2019)

Form of Common Stock Certificate (Filed With SEC on May 8, 2019)

Amendment No. 3 to Capital on DemandTM Sales Agreement, dated March 11, 2019, by and between ARCA biopharma, Inc. and JonesTrading Institutional Services LLC (Filed With SEC on March 11, 2019)

Amendment No. 2 to Capital on DemandTM Sales Agreement, dated January 25, 2019, by and between ARCA biopharma, Inc. and JonesTrading Institutional Services LLC (Filed With SEC on January 25, 2019)

Letter Agreement between ARCA biopharma, Inc. and Medtronic, Inc. dated as of April 17, 2018 (Filed With SEC on April 23, 2018)

Amendment to European Addendum to the Clinical Trial Agreement Between Medtronic and ARCA dated July 10, 2017 (Filed With SEC on November 9, 2017)

AMENDMENT NO. 1 TO CAPITAL ON DEMAND SALES AGREEMENT (Filed With SEC on August 21, 2017)

EUROPEAN ADDENDUM TO THE CLINICAL TRIAL COLLABORATION AGREEMENT BETWEEN MEDTRONIC AND ARCA (Filed With SEC on March 21, 2017)

ARCA biopharma, Inc. Common Stock ($0.001 par value pershare) Capital on Demand Sales Agreement (Filed With SEC on January 11, 2017)

AMENDMENT TO OFFICE LEASE AGREEMENT (Filed With SEC on March 7, 2016)

Change Order Form (Filed With SEC on November 12, 2015)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 11, 2015)

EXHIBIT B-1 FORM OF WARRANT (Filed With SEC on June 11, 2015)

EXHIBIT B-2 FORM OF WARRANT (Filed With SEC on June 11, 2015)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 11, 2015)

Change Order Form (Filed With SEC on May 12, 2015)

CANADIAN ADDENDUM TO THE CLINICAL TRIAL COLLABORATION AGREEMENT BETWEEN MEDTRONIC AND ARCA (Filed With SEC on March 19, 2015)

Change Order Form (Filed With SEC on November 12, 2014)

SECOND AMENDMENT TO CLINICAL TRIAL COLLABORATION AGREEMENT (Filed With SEC on November 12, 2014)

FIRST AMENDMENT TO CLINICAL TRIAL COLLABORATION AGREEMENT (Filed With SEC on August 13, 2014)

PLACEMENT AGENCY AGREEMENT January 21, 2014 (Filed With SEC on February 4, 2014)

Amendment No. 1 to Placement Agency Agreement dated January 21, 2014 (Filed With SEC on February 4, 2014)

COMMON STOCK PURCHASE WARRANT ARCA BIOPHARMA, INC. (Filed With SEC on February 4, 2014)

ARCA biopharma, Inc., Computershare Inc. and Computershare Trust Company, N.A. as Warrant Agent Warrant Agency Agreement Dated as of February 3, 2014 WARRANT AGENCY AGREEMENT (Filed With SEC on February 4, 2014)

ARCA BIOPHARMA, INC. 2013 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:JULY 26, 2013 APPROVED BY THE STOCKHOLDERS:SEPTEMBER 17, 2013 EFFECTIVE DATE: SEPTEMBER 17, 2013 (Filed With SEC on September 23, 2013)

ARCA BIOPHARMA, INC. STOCK OPTION GRANT NOTICE (2013 EQUITY INCENTIVE PLAN) (Filed With SEC on September 23, 2013)

ARCA BIOPHARMA, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2013 EQUITY INCENTIVE PLAN) (Filed With SEC on September 23, 2013)

OFFICE LEASE AGREEMENT CIRCLE POINT PROPERTIES, LLC CIRCLEPOINT TABLE OF CONTENTS (Filed With SEC on August 6, 2013)

COMMON STOCK PURCHASE WARRANT ARCA BIOPHARMA, INC. (Filed With SEC on May 24, 2013)

ARCA biopharma, Inc., Computershare Inc. and Computershare Trust Company, N.A. as Warrant Agent Warrant Agency Agreement Dated as of , 2013 WARRANT AGENCY AGREEMENT (Filed With SEC on May 15, 2013)

COMMON STOCK PURCHASE WARRANT ARCA BIOPHARMA, INC. (Filed With SEC on May 15, 2013)

CLINICAL TRIAL COLLABORATION AGREEMENT (Filed With SEC on April 22, 2013)

PLACEMENT AGENCY AGREEMENT (Filed With SEC on February 1, 2013)

EXHIBIT A COMMON STOCK PURCHASE WARRANT ARCA BIOPHARMA, INC. (Filed With SEC on February 1, 2013)

SUBSCRIPTION AGREEMENT (Filed With SEC on February 1, 2013)

FORM OF WARRANT (Filed With SEC on January 23, 2013)

SUBSCRIPTION AGREEMENT (Filed With SEC on January 23, 2013)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on January 23, 2013)

FORM OF WARRANT (Filed With SEC on December 19, 2012)

SUBSCRIPTION AGREEMENT (Filed With SEC on December 19, 2012)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on December 19, 2012)

AMENDMENT TO THE REGISTRATION RIGHTS AGREEMENT (Filed With SEC on December 19, 2012)

FORM OF WARRANT (Filed With SEC on October 23, 2012)

SUBSCRIPTION AGREEMENT (Filed With SEC on October 23, 2012)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on October 23, 2012)

PLACEMENT AGENCY AGREEMENT (Filed With SEC on August 3, 2012)

EXHIBIT A COMMON STOCK PURCHASE WARRANT ARCA BIOPHARMA, INC. (Filed With SEC on August 3, 2012)

SUBSCRIPTION AGREEMENT (Filed With SEC on August 3, 2012)

WAIVER AND AMENDMENT AGREEMENT (Filed With SEC on May 14, 2012)

FORM OF WARRANT (Filed With SEC on December 22, 2011)

SUBSCRIPTION AGREEMENT (Filed With SEC on December 22, 2011)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on December 22, 2011)

AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT For Licensing Patent Rights (Filed With SEC on August 15, 2011)

FIRST AMENDMENT TO LEASE AGREEMENT (Filed With SEC on June 20, 2011)

LICENSE AGREEMENT (Filed With SEC on May 16, 2011)

PLACEMENT AGENCY AGREEMENT April 18, 2011 (Filed With SEC on April 18, 2011)

EXHIBIT A COMMON STOCK PURCHASE WARRANT ARCA BIOPHARMA, INC. (Filed With SEC on April 18, 2011)

SUBSCRIPTION AGREEMENT (Filed With SEC on April 18, 2011)

8001 Arista Place, Suite 200 Broomfield, CO 80021 Phone: 720 ###-###-####, Fax: 720 ###-###-#### March 31, 2011 (Filed With SEC on April 5, 2011)

8001 Arista Place, Suite 200 Broomfield, CO 80021 Phone: 720 ###-###-####, Fax: 720 ###-###-#### January 20, 2011 (Filed With SEC on January 26, 2011)

8001 Arista Place, Suite 200 Broomfield, CO 80021 Phone: 720 ###-###-####, Fax: 720 ###-###-#### December 21, 2010 (Filed With SEC on December 22, 2010)

8001 Arista Place, Suite 200 Broomfield, CO 80021 Phone: 720 ###-###-####, Fax: 720 ###-###-#### December 8, 2010 (Filed With SEC on December 14, 2010)

SECOND AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on August 10, 2010)

ARCA BIOPHARMA, INC. $20,000,000 Common Stock (par value $0.001 per share) AMENDMENT NO. 1 TO EQUITYDISTRIBUTION AGREEMENT (Filed With SEC on April 30, 2010)

ARCA BIOPHARMA, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on March 4, 2010)

SECTION 1. DEFINITIONS (Filed With SEC on March 4, 2010)

ARCA BIOPHARMA, INC. EQUITY DISTRIBUTIONAGREEMENT (Filed With SEC on December 8, 2009)

LEASE SURRENDER AND TERMINATION AGREEMENT (Filed With SEC on November 16, 2009)

LEASE TERMINATION AND WARRANT PURCHASE AGREEMENT (Filed With SEC on September 24, 2009)

ARCA BIOPHARMA, INC. SEVERANCE BENEFIT PLAN (Filed With SEC on August 10, 2009)

ARCA BIOPHARMA, INC. 2009 REDUCTION IN FORCE (Filed With SEC on August 10, 2009)

NOTICE OF OPTION AMENDMENT (Filed With SEC on August 10, 2009)

ARCA BIOPHARMA, INC. STOCK OPTION AGREEMENT (Filed With SEC on August 10, 2009)

LICENSE AND SUBLICENSE AGREEMENT by and between (Filed With SEC on May 15, 2009)

AMENDMENT TO THE LICENSE AND SUBLICENSE AGREEMENT (Filed With SEC on May 15, 2009)

EXCLUSIVE LICENSE AGREEMENT For Licensing Patent Rights (Filed With SEC on May 15, 2009)

FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT For Licensing Patent Rights (Filed With SEC on May 15, 2009)

SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT For Licensing Patent Rights (Filed With SEC on May 15, 2009)

THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on May 15, 2009)

FOURTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on May 15, 2009)

DIAGNOSTIC COLLABORATION AND OPTION AGREEMENT (Filed With SEC on May 15, 2009)

FIRST AMENDMENT TO DIAGNOSTIC COLLABORATION AND OPTION AGREEMENT (Filed With SEC on May 15, 2009)

PATHEON PROPOSAL :ARC-FYM1-0800-0406-R5 (Filed With SEC on May 15, 2009)

DEVELOPMENT, COMMERCIALIZATION AND LICENSING AGREEMENT BETWEEN (Filed With SEC on May 15, 2009)

AMENDMENT NO. 1 TO DEVELOPMENT, COMMERCIALIZATION AND LICENSING AGREEMENT (Filed With SEC on May 15, 2009)

AMENDMENT NO. 2 TO DEVELOPMENT, COMMERCIALIZATION AND LICENSING AGREEMENT (Filed With SEC on May 15, 2009)

1200 17th Street, Suite 620 Denver, Colorado 80202 Phone: 303 ###-###-####, Fax: 303 ###-###-#### July 27, 2007 (Filed With SEC on May 15, 2009)

8001 Arista Place, Suite 200 Broomfield, CO 80021 Phone: 720 ###-###-####, Fax: 720 ###-###-#### (Filed With SEC on May 15, 2009)

UNIVERSITY OF COLORADO MATERIALS TRANSFER AGREEMENT (Filed With SEC on May 15, 2009)

THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on April 10, 2009)

FOURTH AMENDMENT TO AND ASSUMPTION OF LOAN AND SECURITY AGREEMENT (Filed With SEC on April 10, 2009)

WARRANT TO PURCHASE STOCK (Filed With SEC on March 27, 2009)

AMENDMENT NO. 1 TO WARRANT TO PURCHASE STOCK (Filed With SEC on March 27, 2009)

WARRANT TO PURCHASE STOCK (Filed With SEC on March 27, 2009)

AMENDMENT NO. 1 TO WARRANT TO PURCHASE STOCK (Filed With SEC on March 27, 2009)